media – Page 10 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

accelerating the transition of CLL treatment into a “chemotherapy-free era”.

On January 1, 2026, the new version of the National Reimbursement Drug List officially came into effect. Orelabrutinib (Yinokai®), a novel BTK inhibitor independently developed by Innovent Biologics, has rapidly achieved medical insurance coverage for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL, commonly known as “CLL”), benefiting more patients. On January 17, during the working meeting of the Chinese Society of Clinical Oncology (CSCO) Expert Committee on Leukemia, Lymphoma and Myeloma and the 2026 CSCO Hematologic Oncology Academic Conference held in Haikou, the “Press Conference on the Implementation of Orelabrutinib 1L CLL/SLL Indication Under Medical Insurance Coverage” was successfully held. Several leading experts in the field of lymphoma gathered at the event, including Professor Ma Jun from the Harbin Institute of Hematology and Oncology, Professor Li Jianyong from Jiangsu Provincial People’s Hospital, Professor Qiu Lugui from the Institute of Hematology and Blood Diseases Hospital of the Chinese Academy ...
- Source: drugdu
- 65
- January 20, 2026
Clinical trials successful, development terminated.

Lyra Therapeutics recently decided to terminate all further development of its only candidate drug for the treatment of chronic sinusitis, LYR-210 , and lay off 28 employees, retaining only the CEO and CFO as caretaker managers to find a “strategic alternative.” Just six months ago, this absorbable intranasal implant achieved positive results in a Phase 3 trial, but now it has been shelved by the company itself. LYR-210 is manufactured using Lyra’s proprietary XTreo platform : microcrystalline mometasone furoate is uniformly dispersed within a polylactic-co-glycolic acid copolymer backbone to form a 2-cm-long flexible filament. After simple implantation into the middle nasal meatus by a physician, it continuously releases glucocorticoids for up to 24 weeks, directly acting on the inflamed mucosa. Its target population is patients with chronic sinusitis (CRS) without nasal polyps. In June 2025, the pivotal Phase 3 ENLIGHTEN 2 study of LYR-210 was completed. The trial was a ...
- Source: drugdu
- 57
- January 20, 2026
Takeda Pharmaceutical lays off employees in the US; AstraZeneca acquires remaining Chinese interests in GPC3 CAR-T therapy

Takeda Pharmaceuticals makes major adjustments to its US market strategy. According to recent media reports, Takeda is laying off 243 employees in the United States to cope with the market challenge of Trintellix losing its exclusive sales rights. However, Takeda also plans to hire more than 400 new positions to support the US launch and marketing of several potential new drugs. AstraZeneca continues to deepen its presence in the Chinese market. On January 16, CBMG announced an agreement with AstraZeneca, under which the latter will acquire CBMG’s 50% stake in the development and commercialization rights of C-CAR031 in China. This will grant AstraZeneca exclusive rights to develop, manufacture, and commercialize C-CAR031 globally. Under the terms of the agreement, CBMG will be entitled to receive up to $630 million from AstraZeneca, including upfront payments for the GPC3 project in China, as well as development, regulatory, and sales milestone payments. What other ...
- Source: drugdu
- 49
- January 20, 2026
bioLIVE Japan

Organiser：Informa Markets Time：April 21 -23, 2026 Address：3-21-1 Ariake, Koto-ku, Tokyo 135-0063, Japan Exhibition hall：Tokyo Big Sight International Exhibition Center Product range: From antibody medicines to medium-molecular medicines such as nucleic acids and peptides; to gene and cell medicines. Cutting-edge technologies including biopharmaceutical development outsourcing technologies and devices. About bioLIVE Japan ： The bioLIVE Japan, Japan’s World Biopharmaceutical Technology Exhibition, leads the way in the development of biopharmaceutical technology in Japan. It focuses on life sciences, biotechnology, and innovative drugs, driving innovation and industrial development in the biopharmaceutical sector. Cutting-edge technologies from around the world, including biopharmaceutical development outsourcing technologies and devices, will converge at this event. The previous edition of bioLIVE Japan covered a total area of 30,000 square meters, with 712 exhibiting companies from countries such as China, South Korea, India, Thailand, Russia, the United States, and Germany, attracting 24,800 attendees. Additionally, in recent years, peptide and nucleic ...
- Source: drugdu
- 69
- January 20, 2026
Lunan Pharmaceutical’s Jiali® Oxaliplatin Injection Receives US Marketing Approval

On January 15, Shandong New Era Pharmaceutical Co., Ltd., a subsidiary of Lunan Pharmaceutical Group, received the ANDA 219765 for oxaliplatin injection issued by the U.S. Food and Drug Administration (FDA). This signifies that the product has officially obtained the qualification for commercial sale in the U.S. market. This not only adds an international “passport” to Lunan Pharmaceutical’s anti-tumor product line, but also demonstrates the company’s strong capabilities in quality systems, technology research and development, and international compliance. Oxaliplatin, in combination with 5-fluorouracil and leucovorin (formyltetrahydrofolate), is used in the following applications: (1) Adjuvant therapy for stage III colon cancer after complete resection of the primary tumor. (2) Treatment of advanced colorectal cancer. As an important component of combination chemotherapy regimens, oxaliplatin has less overlap in toxicity with many commonly used antitumor drugs, and has a good safety profile, especially in terms of hematologic and gastrointestinal toxicity. To facilitate the ...
- Source: drugdu
- 74
- January 19, 2026
The second NDA for gumozymab, a new drug application for the treatment of ankylosing spondylitis, has been accepted

Recently, Akeso Biopharma (9926.HK) announced that its novel humanized anti-IL-17A monoclonal antibody, gumozilla (AK111), for the treatment of active ankylosing spondylitis (AS) , has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This signifies that the drug is expected to provide a new treatment option for nearly 4 million AS patients in China . Active ankylosing spondylitis (AS) is the second indication for which gumozimab has received NDA acceptance, and its application for the treatment of moderate to severe psoriasis was accepted by the CDEin January 2025 . Gumochimab is Akeso Biopharma ‘s third blockbuster non-oncology product to enter the market , following inunusicumab (PCSK9) and erogenumab (IL-12/IL-23) . With the successive launches of inunusicumab and erogenumab and their inclusion in the National Reimbursement Drug List , and with products such as Gumochimab and Mandozizumab gradually entering the commercialization stage , along ...
- Source: drugdu
- 68
- January 19, 2026
The clinical trial application for its shingles mRNA vaccine has been officially accepted

Securities Daily Online – January 16, 2026 – Zhifei Biologics stated on an interactive investor platform today that the company has established multiple technology platforms, including mRNA and novel adjuvant platforms. These are used to explore various vaccine development pathways to achieve product iterations and innovative breakthroughs. Its wholly-owned subsidiary, Zhifei Longcom, has officially received the Acceptance Notice for its Investigational New Drug (IND) application for a shingles mRNA vaccine from the National Medical Products Administration (NMPA). For further details, please refer to the “Announcement on the Acceptance of the Clinical Trial Application for Shingles mRNA Vaccine” (No. 2025-67). https://finance.eastmoney.com/a/202601163622203690.html
- Source: drugdu
- 62
- January 19, 2026
3.1 billion! Orthopedic giant announces major acquisition.

According to recent foreign media reports, Smith & Nephew, a global orthopedic giant, announced that it has reached an agreement to acquire Integrity Orthopaedics for a maximum of $450 million (approximately RMB 3.1 billion). Image source: Latest Medical Device News on MassDevice Smith & Nephew will reportedly acquire Integrity Orthopaedics with an initial cash payment of $225 million , and will make additional payments over the next five years, up to a maximum of $225 million , depending on the company’s performance. The deal is expected to close by the end of this month. Founded in 2020, Integrity Orthopaedics is a US-based startup focused on sports medicine, specializing in developing innovative shoulder repair and sports medicine products . According to data from PharmNet Medical Devices, the company already has products on the market. Integrity Orthopaedics has developed a rotator cuff repair system called the Tendon Suture System . In its ...
- Source: drugdu
- 63
- January 19, 2026
The Small Nucleic Acid Track is Ushering in a Major Explosion

Small nucleic acid drugs were one of the focal points at this year’s JPM conference. Overseas giants Alnylam and Ionis have both announced breakthroughs in sales of their core products , reflecting the accelerated commercialization of the entire industry. Meanwhile, Chinese companies are rapidly establishing their positions , with innovative biotechnology companies beginning to export their independently developed technologies and pipelines globally, actively participating in global competition. Large domestic pharmaceutical companies are also accelerating their expansion in this sector; China Biopharmaceutical’s acquisition of Hegia for 1.2 billion yuan indicates that the small nucleic acid technology sector is moving from the periphery to the mainstream. 01 High-growth track the market size of small nucleic acid drugs has grown rapidly with breakthroughs in the field of chronic diseases . According to a Frost & Sullivan report, the global small nucleic acid drug market size is expected to grow from US$5.7 billion in ...
- Source: drugdu
- 78
- January 19, 2026
Zhong Sheng Pharmaceutical’s groundbreaking innovative drug joins forces with Qilu Pharmaceutical to target a market worth tens of billions of yuan

Following the successful inclusion of onrapidil tablets in medical insurance, Zhong Sheng Pharmaceutical…(002317) Innovative drug secures another major order. On January 16, ZS Pharmaceutical disclosed an announcement stating that its subsidiary, ZS Ruicheng, has reached a cooperation agreement with Qilu Pharmaceutical to commercialize its innovative drug, RAY1225 injection, a dual-target receptor ultra-long-acting agonist, to Qilu Pharmaceutical. According to the agreement, ZSRay Technology has authorized Qilu Pharmaceutical to manufacture and commercialize RAY1225 injection in China (including mainland China, Hong Kong, Macau, and Taiwan). ZSRay Technology retains the intellectual property rights under the license.All rights, ownership and interests of RAY1225 injection will be retained by ZSRI, while ZSRI will retain all rights, ownership and interests of RAY1225 injection overseas. Subject to the terms of the agreement, ZSRI will receive a total of upfront and milestone payments of up to RMB 1 billion, including an upfront payment of RMB 200 million and development ...
- Source: drugdu
- 51
- January 19, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.